Cereno Scientific announced that the Company is moving to a new office space at GoCo Health Innovation City in Gothenburg in June 2024. The re- location to GoCo's inspiring community will support the further propelling of Cereno's pipeline and the next step of the Company's growth journey. Cereno Scientific's pipeline comprises late-stage Phase II drug candidate CS1, an HDAC inhibitor with epigenetic effects for the treatment of the rare disease Pulmonary Arterial Hypertension (PAH) with the aim of offering patients an effective, safe and disease-modifying drug; CS014, an HDAC inhibitor with epigenetic effects, being developed for thrombosis prevention, with a first-in-human Phase I study planned to start in Second Quarter 2024; and CS585, a novel IP receptor agonist.

While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding. Cereno Scientific has reported positive findings over the last months, suggesting potential clinical benefit of CS1 in patients. Study completion and topline results are expected during Third Quarter 2024.

On January 30, Cereno was granted approval by the FDA for Expanded Access for CS1 to use in an extension of the ongoing Phase II trial evaluating CS1 in PAH. After eight fruitful years at AstraZeneca's BioVentureHub, Cereno Scientific has chosen to re-locate to GoCo Health Innovation City, to facilitate the next level of growth and development. GoCo Health Innovation City hosts a diverse set of companies, organizations, and individuals working to unlock new solutions to global health challenges.

Here is a world-class innovation cluster for health being created, with collaboration built into the core.